<unk>  (INN), also known as<unk>  (BAN) or propericiazine, is a drug that belongs to the phenothiazine class of typical antipsychotics.<unk>  is not approved for sale in the United States. It is commonly sold in Canada, Italy and Russia under the tradename Neuleptil and in United Kingdom and Australia under the tradename Neulactil. Medical uses== The primary uses of<unk>  include in the short-term treatment of severe anxiety or tension and in the maintenance treatment of psychotic disorders such as schizophrenia. There is insufficient evidence to determine whether<unk>  is more or less effective than other antipsychotics. A 2014 systematic review compared<unk>  with typical antipsychotics for schizophrenia: +<unk>  versus typical antipsychotic for schizophrenia Summary On the basis of very low quality evidence it is not possible to determine the effects of<unk>  in comparison with antipsychotics such as chlorpromazine or trifluoperazine for the treatment of schizophrenia. There is some evidence, however, that<unk>  may be associated with a higher incidence of extrapyramidal side effects than other antipsychotics. Outcome Findings in words Findings in numbers Quality of evidence Global state Not improvedFollow-up: 6-12 weeks<unk>  may increase the risk of being 'not improved', but, at present it is not possible to be confident about the difference between people receiving<unk>  and those given chlorpromazine or trifluoperazine. Data supporting this finding are very limited. RR 1.24 (0.93 to 1.66) Very low Adverse events Extrapyramidal side effectFollow-up: 6-12 weeks<unk>  may reduce the chance of experiencing the movement disorder, compared with chlorpromazine or trifluoperazine, but, at present there is only very limited data supporting this finding. RR 0.59 (0.38 to 0.89) Very low Leaving the study early For any reasonsFollow-up: 9-12 weeks<unk>  may reduce the chance of leaving the study early, but, at present it is not possible to be confident about the difference between the two treatments and data supporting this finding are very limited. RR 0.46 (0.11 to 1.9) Very low Missing outcomes No study reported any data on outcomes such as relapse, mental state, cost-effectiveness, and information relating to behavior<unk>  has also been studied in the treatment of opioid dependence.
Periciazine
Quinfamide
Ajmalicine
Methaniazide
Sakacin
Gendicine
Pingyangmycin
Diazoxide